M&A work in the pharmaceutical industry continued apace last month, with White & Case’s London office winning its first mandate from CVC Capital Partners, as the private equity firm led a club of investors in buying a controlling stake in Simpson Thacher & Bartlett-client Alvogen.
Although White & Case has a historic relationship with CVC stateside, the deal for the $2bn pharma company is the first to be led out of London for the European private equity fund, which has previously turned to a raft of firms for its corporate work, including Clifford Chance and Cleary Gottlieb Steen & Hamilton. Private equity heavyweight Ian Bagshaw in London, alongside Oliver Brahmst from New York, led the firm’s team, which included New York partner Brian Smarsh and London partners Justin Wagstaff and Marcus Booth.
Subscriber Access
You must be logged in to view full premium content.
